AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26909960 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional medicine).
Number of subjects: 82
Study 24658769 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 779
Study 24658769 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 779
Study 22382219 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (0.9%) hydration at 1 mL/kg/h for 12 hours before and 24 hours after PCI
Number of subjects: 240
Study 20801446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 supplementation
Number of subjects: 65
Study 20801446 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 65
Study 20801446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 17096666 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg/ml intravenously every 6 h during the first post-operative day (total, 400 mg/24 h)
Number of subjects: 63
Study 17096666 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 63
Study 15846274 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion-implanted Arthos Inert stent (group 1)
Number of subjects: 225
Study 15846274 — intervention group
Group type: COMPARATOR
Intervention: Bare metal Arthos stent (group 2)
Number of subjects: 225
Study 11827256 — intervention group
Group type: EXPERIMENTAL
Intervention: Er‐YAG laser irradiation at 2 Hz and 180 mJ with water‐cooling
Number of subjects: 0
Study 11827256 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid‐etching with 35% H3PO4
Number of subjects: 0
Study 11827256 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐ and acid‐etched
Number of subjects: 0
Study 11827256 — intervention group
Group type: COMPARATOR
Intervention: Acid‐etching alone
Number of subjects: 0
Study 10422481 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session psychoeducational programme for patients with schizophrenia and their relatives
Number of subjects: 0
Study 7776163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand toothbrush
Number of subjects: 58
Study 7776163 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic toothbrush 1
Number of subjects: 58
Study 7776163 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic toothbrush 2
Number of subjects: 58
Study 7776163 — intervention group
Group type: COMPARATOR
Intervention: No brushing (control)
Number of subjects: 58
Study 2104438 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of sodium heparin
Number of subjects: 94
Study 2104438 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of sodium heparin
Number of subjects: 94
Study 697222 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking marihuana cigarettes containing 6 mg of delta‐9‐tetrahydrocannabinol
Number of subjects: 14
Study 697222 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 14
Study 30802822 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine 80 mg/m2 (first cycle at 60 mg/m2, escalated to 80 mg/m2 in the absence of grade 3/4 toxicity)
Number of subjects: 131
Study 30802822 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paclitaxel 80 mg/m2 on days 1, 8, and 15 every 3 weeks
Number of subjects: 131
Study 30802822 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 131
Study 30802822 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paclitaxel
Number of subjects: 131
Study 28389572 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 9102
Study 28389572 — intervention group
Group type: COMPARATOR
Intervention: Functional testing (exercise electrocardiography, nuclear stress, or stress echocardiography)
Number of subjects: 9102
Study 28389572 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 9102
Study 28389572 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 9102
Study 28389572 — intervention group
Group type: EXPERIMENTAL
Intervention: Reclassification of 2714 patients with normal functional test as mildly abnormal
Number of subjects: 9102
Study 26218258 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up clinic (intervention)
Number of subjects: 209
Study 26218258 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 209
Study 24076689 — intervention group
Group type: EXPERIMENTAL
Intervention: External valvuloplasty for small subcutaneous veins
Number of subjects: 39
Study 24076689 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedures (control group)
Number of subjects: 39
Study 24076689 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with venous reflux
Number of subjects: 39
Study 24076689 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without venous reflux
Number of subjects: 39
Study 21880848 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D (1 g Ca/400 IU vitamin D daily)
Number of subjects: 36482
Study 20027426 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea rinse (1 min)
Number of subjects: 10
Study 20027426 — intervention group
Group type: COMPARATOR
Intervention: Water rinse (control, 1 min)
Number of subjects: 10
Study 20027426 — intervention group
Group type: EXPERIMENTAL
Intervention: ERO+I-ABR (immediate toothbrushing after erosion)
Number of subjects: 10
Study 20027426 — intervention group
Group type: EXPERIMENTAL
Intervention: ERO+30-min-ABR (toothbrushing 30 min after erosion)
Number of subjects: 10
Study 16446329 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y‐muHMFG1 plus standard treatment
Number of subjects: 447
Study 16446329 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 447
Study 15242142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonorganizational religiosity
Number of subjects: 91
Study 15242142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic religiosity
Number of subjects: 91
Study 15242142 — intervention group
Group type: EXPERIMENTAL
Intervention: Low religiosity
Number of subjects: 91
Study 15242142 — intervention group
Group type: COMPARATOR
Intervention: Religiosity or spirituality
Number of subjects: 91
Study 11866284 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose HBV vaccination (40 microg administered monthly for 3 months)
Number of subjects: 152
Study 11866284 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose HBV vaccination (booster dose of 80 microg for nonresponders)
Number of subjects: 152
Study 11866284 — intervention group
Group type: COMPARATOR
Intervention: Control group (26 individuals with no evidence of liver disease receiving the same vaccination schedule)
Number of subjects: 152
Study 9642936 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of inactivated influenza vaccine
Number of subjects: 71
Study 9642936 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of inactivated influenza vaccine
Number of subjects: 71
Study 8083453 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (15 mg weekly)
Number of subjects: 24
Study 8083453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2576861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 287
Study 2576861 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 287
Study 335348 — intervention group
Group type: EXPERIMENTAL
Intervention: H. influenzae type b vaccine
Number of subjects: 100000
Study 335348 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A meningococcal vaccine)
Number of subjects: 100000
Study 28598446 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop on construction of MCQs
Number of subjects: 16
Study 26456573 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 90 mg/m² IV (days 1, 8, and 15) and bevacizumab 10 mg/kg IV (days 1, 15) with everolimus 10 mg daily (Arm 1)
Number of subjects: 113
Study 26456573 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 90 mg/m² IV (days 1, 8, and 15) and bevacizumab 10 mg/kg IV (days 1, 15) with placebo (Arm 2)
Number of subjects: 113
Study 26456573 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Arm 1 and Arm 2)
Number of subjects: 113
Study 26456573 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 1 (everolimus)
Number of subjects: 113
Study 23245582 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg IV iron sucrose
Number of subjects: 145
Study 23245582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg IV iron sucrose
Number of subjects: 145
Study 23245582 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg IV iron sucrose
Number of subjects: 145
Study 23245582 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosing regimens
Number of subjects: 145
Study 21273758 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact catheter
Number of subjects: 28
Study 21273758 — intervention group
Group type: COMPARATOR
Intervention: Regular catheter
Number of subjects: 28
Study 19393845 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoprofen 100 mg + acetaminophen 1000 mg
Number of subjects: 76
Study 19393845 — intervention group
Group type: COMPARATOR
Intervention: acetaminophen 1000 mg
Number of subjects: 76
Study 19393845 — intervention group
Group type: COMPARATOR
Intervention: ketoprofen 100 mg
Number of subjects: 76
Study 19393845 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study 17078155 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive treatment
Number of subjects: 204
Study 17078155 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based antihypertensive treatment
Number of subjects: 204
Study 15669418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (IV bolus of 2mg/kg in 15 minutes, followed by maintenance infusion of 0.0067 mg/kg/min until conversion to sinus rhythm or for up to 90 minutes)
Number of subjects: 75
Study 15669418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching saline solution administered in the same fashion)
Number of subjects: 75
Study 15669418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 75
Study 11211369 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine combined with cognitive-behavioral therapy
Number of subjects: 63
Study 11211369 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with cognitive-behavioral therapy
Number of subjects: 63
Study 11211369 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (including psychotropic medication and outpatient therapy)
Number of subjects: 63
Study 11211369 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline somatic complaints
Number of subjects: 63
Study 9368196 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram infusion (20 mg i.v. at 14:20-14:50 h) after a night of undisturbed sleep
Number of subjects: 7
Study 9368196 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram infusion (20 mg i.v. after a night of sleep deprivation
Number of subjects: 7
Study 28895428 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (10 patients)
Number of subjects: 20
Study 28895428 — intervention group
Group type: COMPARATOR
Intervention: Saline (10 patients, control group)
Number of subjects: 20
Study 27537603 — intervention group
Group type: EXPERIMENTAL
Intervention: Kestose, administered orally every day for 12 weeks
Number of subjects: 65
Study 27537603 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 65
Study 25903295 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered results
Number of subjects: 0
Study 25903295 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pass filters with cutoffs at 0.3 Hz and above
Number of subjects: 0
Study 24330422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (100,000 IU for infants <12 months & 200,000 IU for children >12 months) and 10 mg daily zinc for 6 months
Number of subjects: 200
Study 24330422 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A and zinc placebo for 6 months
Number of subjects: 200
Study 20218404 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 0
Study 20218404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mononarcosis with ketamine
Number of subjects: 0
Study 17383342 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) for 3 weeks before surgery
Number of subjects: 30
Study 17383342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15102997 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (250 mg of tegafur per square meter of body-surface area per day) for two years
Number of subjects: 999
Study 15102997 — intervention group
Group type: COMPARATOR
Intervention: No treatment (observation)
Number of subjects: 999
Study 11476795 — intervention group
Group type: EXPERIMENTAL
Intervention: 17alpha-hydroxyprogesterone caproate (17-HPC) 341 mg every 3 days
Number of subjects: 300
Study 11476795 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (P) 50 mg daily
Number of subjects: 300
Study 9601347 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled condition
Number of subjects: 15
Study 9601347 — intervention group
Group type: COMPARATOR
Intervention: Unsaddled condition
Number of subjects: 15
Study 7975797 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin) - 2500‐5000 anti‐Xa‐units once daily for 10 days
Number of subjects: 130
Study 7975797 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (Liquemin) - 5000 IU two to three times daily for 10 days
Number of subjects: 130
Study 7975797 — intervention group
Group type: COMPARATOR
Intervention: Comparison of anti‐Xa‐activity
Number of subjects: 130
Study 7975797 — intervention group
Group type: COMPARATOR
Intervention: Other coagulation parameters (antithrombin III, partial thrombin time, thrombin time)
Number of subjects: 130
Study 7975797 — intervention group
Group type: COMPARATOR
Intervention: Hematologic parameters and liver enzymes
Number of subjects: 130
Study 7975797 — intervention group
Group type: COMPARATOR
Intervention: Heparin induced thrombocytopenia
Number of subjects: 130
Study 2692199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) - 60 micrograms, 3 ampoules, infused daily over 3 hours for 6 weeks
Number of subjects: 42
Study 2692199 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 3 ampoules of alpha-CD, infused daily over 3 hours for 6 weeks
Number of subjects: 42
Study 2692199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1)
Number of subjects: 42
Study 2692199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 782624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lincomycin
Number of subjects: 62
Study 782624 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 31525137 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RGT) program plus physiotherapy (n=6)
Number of subjects: 12
Study 31525137 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy only (control group; n=6)
Number of subjects: 12
Study 30054906 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate hydration with nitrates (isosorbide dinitrate combined with isotonic saline at 1.5 mL/kg/h during perioperative period)
Number of subjects: 394
Study 30054906 — intervention group
Group type: COMPARATOR
Intervention: Routine hydration (control group)
Number of subjects: 394
Study 30054906 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate hydration with nitrates
Number of subjects: 394
Study 28856749 — intervention group
Group type: EXPERIMENTAL
Intervention: TensLess® supplementation
Number of subjects: 13
Study 25952653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention (home BP telemonitors, medication adjustments by pharmacists, lifestyle advice via telephone visits)
Number of subjects: 403
Study 25952653 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no telemonitoring intervention)
Number of subjects: 403
Study 25952653 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 403
Study 23657490 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and peer support (EPS)
Number of subjects: 135
Study 23657490 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and peer support with access to an outpatient clinic (EPSOC)
Number of subjects: 135
Study 23657490 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 135
Study 21720260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B (n = 58)
Number of subjects: 119
Study 21720260 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet A (n = 61)
Number of subjects: 119
Study 19595382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean‐like diet
Number of subjects: 563
Study 19595382 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (2.4 g/d)
Number of subjects: 563
Study 19595382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (diet and n-3 PUFA)
Number of subjects: 563
Study 17719292 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c <4.9%
Number of subjects: 2841
Study 17719292 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c 4.9%-5.1%
Number of subjects: 2841
Study 17719292 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c >5.1%
Number of subjects: 2841
Study 17719292 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 2841
Study 17719292 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in HbA1c level
Number of subjects: 2841
Study 17719292 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-known diabetes
Number of subjects: 2841
Study 15549977 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TE) measurements through various methods (aortic, mitral, pulmonary valves, etc.)
Number of subjects: 30
Study 15549977 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeball guessing
Number of subjects: 30
Study 15549977 — intervention group
Group type: EXPERIMENTAL
Intervention: Best transoesophageal echocardiography measurements (transaortic measurements using triangular shape assumption)
Number of subjects: 30
Study 11566079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (15 mg) plus fentanyl (25 microgram)
Number of subjects: 20
Study 11566079 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (15 mg) alone
Number of subjects: 20
Study 9556011 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 83
Study 9556011 — intervention group
Group type: EXPERIMENTAL
Intervention: ALEC
Number of subjects: 83
Study 9556011 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 83
Study 7608841 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried dura mater membrane
Number of subjects: 69
Study 2979276 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid antacid (neutralizing capacity 120 mmol per day)
Number of subjects: 125
Study 2979276 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cimetidine
Number of subjects: 125
Study 2979276 — intervention group
Group type: COMPARATOR
Intervention: Placebo pain tablets
Number of subjects: 125
Study 2979276 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of therapy (general)
Number of subjects: 125
Study 31430366 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic Review Kit (ARK) intervention
Number of subjects: 0
Study 28251937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese diet (SFA: 12.4-12.6% of calories)
Number of subjects: 92
Study 28251937 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter diet (SFA: 12.4-12.6% of calories)
Number of subjects: 92
Study 28251937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese diet
Number of subjects: 92
Study 28251937 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter diet
Number of subjects: 92
Study 28251937 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate diet (fat: 25%, SFAs: 5.8%)
Number of subjects: 92
Study 28251937 — intervention group
Group type: COMPARATOR
Intervention: MUFA-rich diet (SFAs: 5.8%, MUFAs: 19.6%)
Number of subjects: 92
Study 28251937 — intervention group
Group type: COMPARATOR
Intervention: PUFA-rich diet (SFAs: 5.8%, PUFAs: 11.5%)
Number of subjects: 92
Study 28251937 — intervention group
Group type: COMPARATOR
Intervention: All diets
Number of subjects: 92
Study 25546444 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 SET
Number of subjects: 48
Study 25546444 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 SETS
Number of subjects: 48
Study 25546444 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 SETS
Number of subjects: 48
Study 25546444 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 23543264 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased FV consumption (≥ 5 portions/day) for 16 weeks
Number of subjects: 83
Study 23543264 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (≤ 2 portions/day)
Number of subjects: 83
Study 20528109 — intervention group
Group type: EXPERIMENTAL
Intervention: ADDED (dietary plus physical activity change)
Number of subjects: 29
Study 20528109 — intervention group
Group type: COMPARATOR
Intervention: STANDARD (primarily dietary change)
Number of subjects: 29
Study 19339043 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-unit fiber-reinforced resin composite (FRC) fixed partial dentures (FPDs)
Number of subjects: 52
Study 19339043 — intervention group
Group type: COMPARATOR
Intervention: Surface FPDs with additional mechanical retention
Number of subjects: 52
Study 19339043 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface FPDs
Number of subjects: 52
Study 17294208 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency assisted uvulopalatoplasty (RAUP)
Number of subjects: 40
Study 17294208 — intervention group
Group type: COMPARATOR
Intervention: Submucosal channeling of the palate
Number of subjects: 40
Study 14991374 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone and celecoxib
Number of subjects: 50